期刊文献+

Skp2和p27在乳腺癌分子亚型中的表达及与基底样型乳腺癌的关系 被引量:3

Expression of Skp2 and p27 in molecular subtypes of breast carcinoma and their relation with basal-like breast carcinoma
下载PDF
导出
摘要 目的探讨Skp2和p27在乳腺癌分子亚型中的表达及与基底样型乳腺癌的相关性。方法 1 452例乳腺癌标本制作组织芯片,免疫组化MaxVision快捷法检测ER、PR、HER2、CK5/6和EGFR,按照Nielsen标准进行分子分型。同时检测Skp2和p27。结果在乳腺癌基底样型、HER2过表达、裸表达型、腺腔A型、腺腔B型中,Skp2表达率为63.3%、51.9%、53.1%、21.3%和13.7%;p27表达率为35.2%、46.3%、41.4%、55.9%和63.0%。Skp2在基底样型、HER2过表达型和裸表达型的表达中显著高于腺腔A和B型(P<0.01);而p27在基底样型、HER2过表达型和裸表达型中的表达率显著低于腺腔A和B型(P<0.05)。Skp2和p27的表达水平与ER表达相关(P<0.01)。Skp2和p27的表达在基底样型乳腺癌中呈负相关(P<0.01)。结论 Skp2的高表达及p27的失表达可能与ER阴性乳腺癌的发生和发展有关,并且Skp2在基底样型乳腺癌的发生、发展中起重要作用。在基底样型乳腺癌中二者基因相关性的研究为其发病机制的阐明提供帮助。 Objective To study the expression of Skp2 and p27 in the molecular subtypes of breast carcinoma and their correlation with basal-like breast carcinoma.Methods Immunohistochemistry was used to detect the expression of ER,PR,HER2,CK5 /6 and EGFR on a tissue microarray containing 1 452 cases of invasive breast carcinomas.Based on the results,the cases were categorized according to Nielsen criteria.Immunohistochemical MaxVision method was also used to detect the expression of Skp2 and p27 on a tissue microarray.Results Positive expression rates of Skp2 protein in basal-like,HER2 over-expression,null,luminal A and luminal B substypes were 63.3%,51.9%,53.1%,21.3% and 13.7%,respectively;the expression rates of p27 protein were 35.2%,46.3%,41.4%,55.9% and 63.0%,respectively.Like the phenotypes of basal-like,HER2 over-expression and null,positive expression of Skp2 protein were remarkably higher than luminal A subtype and luminal B subtype(P〈0.01);positive expression of p27 protein were remarkably lower than luminal A subtype and luminal B subtype(P〈0.05).The expression of Skp2 protein and p27 protein was associated with the expression of ER protein(P〈0.01).Expression of Skp2 was negatively correlated with expression of p27 in basal-like breast carcinoma(P 0.001).Conclusion The over-expression of Skp2 protein and loss of p27 expression may be related to the development of ER-negative breast cancer.Skp2 might play important roles in the development of basal-like breast carcinoma.The research of the relationship between Skp2 and p27 in basal-like breast carcinoma may help for illuminating the pathogenesis.
出处 《诊断病理学杂志》 CSCD 2010年第6期411-415,共5页 Chinese Journal of Diagnostic Pathology
关键词 乳腺肿瘤 分子亚型 SKP2 P27 基因 Breast neoplasms Molecular subtypes Skp2 p27 Genes
  • 相关文献

参考文献25

  • 1杨光之,皋岚湘,丁华野.乳腺基底细胞样癌[J].诊断病理学杂志,2007,14(4):241-244. 被引量:24
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res,2004,10 (16):5367-5374.
  • 4Tsuda H,Takarabe T,Hasegawa T,et al.Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones[J].Hum Pathol,1999,30(10):1134-1139.
  • 5Lakhani SR,Reis-Filho JS,Fulford L,et al.Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype[J].Clin Cancer Res,2005,11(14):5175-5180.
  • 6Zhang H,Kobayashi R,Galaktionov K,et al.p19Skpl and p45Skp2 are essential elements of the cyclinA-CDK2 S phase kinase[J].Cell,1995,82(6):915-925.
  • 7Ganoth D,Bornstein G,Ko TK,et al.The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27[J].Nature Cell Biol,2001,3(3):321-324.
  • 8Kudo Y,Kitajima S,Sato S,et al.High expression of S-phase kinase-interacting protein 2,human F-box protein,correlates with poor prognosis in oral squamous cell carcinomas[J].Cancer Res,2001,61(19):7044-7047.
  • 9Gstaiger M,Jordan R,Lim M,et al.Skp2 is oncogenic and overexpressed in human cancers[J].Proc Natl Acad Sci USA,2001,98(9):5043-5048.
  • 10Latres E,Chiarle R,Schulman BA,et al.Role of the F-box protein Skp2 in lymphomagenesis[J].Proc Natl Acad Sci USA,2001,98(5):2515-2520.

二级参考文献37

  • 1Watters AD,Going JJ,Cooke GT,et al.Chromosome 17 aneusomy is associated with poor prognostic factors in invesive breast carcinoma.Breast Cancer Res Treat,2003,77:109-114.
  • 2Bilous M,Morey A,Armes J,et al.Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.Pathology,2006,38:120-124.
  • 3Goldhirsch A,Glick JH,Gelber RD,et al.Meeting highlights:international expert consensus on the primary therapy of early breast cancer 2005.Annals Oncol,2005,16:1569-1583.
  • 4The Center For Devices and Radiological Health (CDRH) of the Food and Drug Administration.A document of evaluation about the PathVysionTM HER-2 DNA Probe Kit of Vysis,INC.for detecting amplification of the HER-2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed,paraffin-embedded human breast cancer tissue specimens.[2001-12-31].http://www.fda.gov/cdrh/pmapage.html.
  • 5Shak S.Overview of the trastuzumab (Hereeptin) anti-HER2monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer.Herceptin Multinational Investigator Study Group.Semin Oncol,1999,26(4 Suppl 12):71-77.
  • 6Hammock L,Lewis M,Philips,C,et al.Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.Hum Pathol,2003,34:1043-1047.
  • 7北京市发展和改革委员会.关于公布荧光原位杂交基因检测(FISH)等新增医疗服务价格项目的通知.京发改[2006]1376号.http://www.bjpc.gov.cn/tztg/200608/t129145.btm.
  • 8Hicks DG,Tubbs RR.Assessment of the Her2 status in breast cancer by fluorescence in situ hybridization:a technical review with interpretive guidelines.Hum Pathol,2005,36:250-261.
  • 9Wang S,Hossein Saboorian H,Frenkel EP,et al.Aneusomy 17 in breast cancer:its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.Mod Pathol,2002,15:137-145.
  • 10Risio M,Casorzo L,Redana S,et al.HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment.Oncol Rep,2005,13:305-309.

共引文献184

同被引文献12

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部